Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962700 | 0.98 | SIGMAR1 (0.54) | SIGMAR1HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL22642134 | 0.88 | SIGMAR1 (0.49) | SIGMAR1HRH3SLC6A3SLC6A4 | |
| SCHEMBL10058642 | 0.87 | HRH3 (0.48) | SIGMAR1HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL17526221 | 0.85 | HRH3 (0.46) | SIGMAR1HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL17528500 | 0.85 | HRH3 (0.46) | SIGMAR1HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL3563316 | 0.84 | SIGMAR1 (0.43) | SIGMAR1HRH3DRD2 | |
| SCHEMBL13701445 | 0.83 | SIGMAR1 (0.50) | SIGMAR1HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL30552770 | 0.83 | SIGMAR1 (0.51) | SIGMAR1HRH3 | |
| SCHEMBL4617835 | 0.81 | SIGMAR1 (0.49) | SIGMAR1HRH3SLC6A3SLC6A4DRD2 | |
| SCHEMBL41978 | 0.80 | SIGMAR1 (0.41) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | SIGMAR1 2658/4885HRH3 4106/4885CARM1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.